financetom
Business
financetom
/
Business
/
K2 Capital Acquisition Corporation Announces Closing of its Upsized $138,000,000 Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Units
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
K2 Capital Acquisition Corporation Announces Closing of its Upsized $138,000,000 Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Units
Mar 11, 2026 2:24 AM

NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corporation ( KTWOU ) (the "Company") today announced the closing of its upsized initial public offering of 13,800,000 units at $10.00 per unit, which includes the exercise in full by the underwriters of their option to purchase an additional 1,800,000 units, with each unit consisting of one Class A ordinary share and one right to receive one-fifth (1/5) of one Class A ordinary share at the closing of the Company’s initial business combination. The units began to trade on the Nasdaq Global Market ("Nasdaq") under the ticker symbol "KTWOU" on January 29, 2026, and the Class A ordinary shares and rights were listed on Nasdaq under the symbols "KTWO" and "KTWOR," respectively.

D. Boral Capital (“D. Boral”), is acting as the sole book-running manager for the offering. Loeb & Loeb LLP is serving as legal advisor to the Company. Freshfields US LLP is serving as legal advisor to D. Boral.

A registration statement on Form S-1, as amended (the "Registration Statement") relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on January 28, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from D. Boral Capital, 590 Madison Ave 39th floor, New York, NY 10022, by email at [email protected], or by accessing the SEC's website, www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About K2 Capital Acquisition Corporation ( KTWOU )

K2 Capital Acquisition Corporation ( KTWOU ) is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements," including with respect to the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Karan Thakur

Chairman & Chief Executive Officer

Email: [email protected]

Phone: +1-236-521-6500

Image: https://www.globenewswire.com/newsroom/ti?nf=OTY0NjQxNiM3NDAyMzk5IzUwMDE1Nzg2OA==

Image: https://ml.globenewswire.com/media/ZmRiMGUwMDItYTNjYy00NzYwLTgxYmItODg2Mzg2MjVlY2I1LTUwMDE1Nzg2OC0yMDI2LTAxLTMwLWVu/tiny/K2-Capital-Acquisition-Corpora.png Image: Primary Logo

Source: K2 Capital Acquisition Corporation ( KTWOU )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Leidos Holdings Says NSA has Awarded it a $390 Million Contract
Leidos Holdings Says NSA has Awarded it a $390 Million Contract
Apr 3, 2025
08:58 AM EDT, 04/03/2025 (MT Newswires) -- Leidos Holdings ( LDOS ) said Thursday the National Security Agency has awarded it a base-plus-four-option-years contract with a $390 million ceiling value to provide signals intelligence capabilities. The company said it is to provide a wide range of technical, engineering, systems administration and management functions for signals intelligence for the agency. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Sonim Technologies Receives $4 per Share Takeover Offer From Orbic
Sonim Technologies Receives $4 per Share Takeover Offer From Orbic
Apr 3, 2025
08:57 AM EDT, 04/03/2025 (MT Newswires) -- Sonim Technologies ( SONM ) said Thursday that it has received an unsolicited, non-binding offer from Orbic North America to acquire all of its outstanding shares for $4 each in cash. The company said it is reviewing the proposal while it consults with its legal and financial advisors. We appreciate Orbic's offer and...
Aldeyra Therapeutics Gets US FDA Letter for Resubmission of New Drug Application for Eye Disease Treatment - Shares Slump Pre-Bell
Aldeyra Therapeutics Gets US FDA Letter for Resubmission of New Drug Application for Eye Disease Treatment - Shares Slump Pre-Bell
Apr 3, 2025
08:59 AM EDT, 04/03/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday that it has received a complete response letter from the US Food and Drug Administration for the resubmission of its new drug application for its potential dry eye disease treatment, reproxalap. The company said that no manufacturing or safety issues with reproxalap were identified, but the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved